Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GoodRx Holdings, Inc.GDRX · Entity 4838 | Chief Accounting Officer | March 08, 2026 | March 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GoodRx Holdings, Inc.
Report date March 08, 2026 · Filed March 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 183,061 |
Ending reported balance
After 2026-03-08 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-03-08 · Exercise / conversion · Acquired 10,201 · Balance 185,949 F1: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. Row 2 · 2026-03-08 · Tax withholding · Disposed 4,201 · Balance 181,748 Row 3 · 2026-03-08 · Exercise / conversion · Acquired 2,233 · Balance 183,981 F1: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. Row 4 · 2026-03-08 · Tax withholding · Disposed 920 · Balance 183,061 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 20,402 |
Reported balance
After 2026-03-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-08 · Exercise / conversion · Disposed 10,201 · Balance 20,402 F1: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2: The restricted stock unit award vested as to 6.25% of the underlying shares on December 8, 2022 with the remaining 93.75% vesting in approximately equal quarterly installments thereafter for 15 quarters. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 17,858 |
Reported balance
After 2026-03-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-08 · Exercise / conversion · Disposed 2,233 · Balance 17,858 F1: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F3: The restricted stock unit award will vest as to 6.25% of the underlying shares on June 8, 2024 with the remaining 93.75% vesting in approximately equal quarterly installments thereafter for 15 quarters. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Class A common stock.
F2: The restricted stock unit award vested as to 6.25% of the underlying shares on December 8, 2022 with the remaining 93.75% vesting in approximately equal quarterly installments thereafter for 15 quarters.
F3: The restricted stock unit award will vest as to 6.25% of the underlying shares on June 8, 2024 with the remaining 93.75% vesting in approximately equal quarterly installments thereafter for 15 quarters.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2022 Filed Sep 26, 2022 16:47 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | GrantRestricted Stock Unit · Derivative | 163,212 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-032044 · doc4.xml · derivative · entry 1 Nabiey Romin · CIK 0001924892 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,212 Underlying: Class A Common Stock · 163,212 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock unit award vests as to 6.25% of the underlying shares on December 8, 2022 with the remaining 93.75% to vest in approximately equal quarterly installments thereafter for 15 quarters. F2 · derivative.expiration_date: The restricted stock unit award vests as to 6.25% of the underlying shares on December 8, 2022 with the remaining 93.75% to vest in approximately equal quarterly installments thereafter for 15 quarters. Read SEC document |
| July 15, 2022 Filed Oct 18, 2022 16:15 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionRestricted Stock Unit · Derivative | 2,606 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-033739 · doc4.xml · derivative · entry 5 Nabiey Romin · CIK 0001924892 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,060 Underlying: Class A Common Stock · 2,606 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vested 19% on April 15, 2021, and the remaining 81% vested or will vest in equal quarterly installments over the following 15 quarters. F2 · derivative.expiration_date: The restricted stock units vested 19% on April 15, 2021, and the remaining 81% vested or will vest in equal quarterly installments over the following 15 quarters. Read SEC document |
| July 15, 2022 Filed Oct 18, 2022 16:15 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Tax withholdingClass A Common Stock | 902 | $6.15 | $5,547.30 |
DisclosureSEC source: 0000899243-22-033739 · doc4.xml · nonDerivative · entry 2 Nabiey Romin · CIK 0001924892 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,873 Read SEC document |
| July 15, 2022 Filed Oct 18, 2022 16:15 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionClass A Common Stock | 2,606 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033739 · doc4.xml · nonDerivative · entry 1 Nabiey Romin · CIK 0001924892 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.